Baxter, MNNCT05612100Now EnrollingIRB Ready

Breast Carcinoma Clinical Trial in Baxter, MN

Access cutting-edge breast carcinoma treatment through this clinical trial at a research site in Baxter. Study-provided care at no cost to qualified participants.

Sponsored by Mayo Clinic

Quick Self-Assessment

See if you qualify for this Baxter location

Preparing your pre-screening questions…

Expert Care in Baxter

Access breast carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related breast carcinoma treatment provided free

Apply for This Baxter Location

Check if you qualify for this breast carcinoma clinical trial in Baxter, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Baxter

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Baxter site if eligible
  4. 4Begin participation

About This Breast Carcinoma Study in Baxter

This study evaluates endocrine therapy-induced alopecia among postmenopausal and premenopausal female patients with breast cancer. Alopecia is one of the most feared side effects of cancer-directed therapy, causing distress in women starting treatment for breast cancer. While alopecia is a well-known side effect of many chemotherapy drugs, it has also been reported by women undergoing endocrine therapy. Despite the frequent reports of alopecia related to endocrine therapy, hair loss is rarely reported as a side effect of endocrine therapy and the exact characterization of alopecia is not well understood. By having postmenopausal and premenopausal breast cancer patients describe their hair loss symptoms experienced while undergoing endocrine therapy, researchers may be able to better characterize the incidence, timing, duration, and severity of alopecia and whether the different types of endocrine therapy cause more or less trouble in this regard.

Sponsor: Mayo Clinic

Who Can Participate

Inclusion Criteria

Age \>= 18 years
Women with a diagnosis of breast cancer who are being treated with curative intent, with the one exception being women who are receiving CDK4/6 inhibitors (these patients being allowed to have more advanced disease)
Provide informed consent
Ability to complete questionnaire(s) by themselves or with assistance
Filling into one of the 5 groups (understanding that groups will close once they complete their accrual goals of 30 patients)
Willingness to complete questionnaires every 3 months
Ability to complete the first questionnaire within 2 weeks of therapy initiation (for the four arms that are receiving adjuvant hormonal therapy)
For patients starting tamoxifen or an aromatase inhibitor: within 2 weeks of starting tamoxifen or aromatase inhibitor
For patients starting a CDK 4/6 inhibitor: within 2 weeks of starting the CDK 4/6 inhibitor (patients may have started an aromatase inhibitor at any time prior to initiation of CDK 4/6 inhibitor).

Exclusion Criteria

Verbal baseline alopecia \>= 2 on an 11 point scale (from none = 0 to severe = 10). The question to use for this item is: Please rate your hair thinning or loss on a scale from 0 to 10, with 0 being no hair loss and 10 being complete hair loss
Planned receipt of chemotherapy or another cancer-directed therapy concurrently (e.g., everolimus, etc.; note that a CDK4/6 inhibitor is allowed within cohort 3)
Prior use of endocrine therapy for breast cancer
Receipt of chemotherapy over the previous 6 months

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Baxter?

Yes, this clinical trial (NCT05612100) has an active research site in Baxter, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Breast Carcinoma Treatment Options in Baxter, MN

If you're searching for breast carcinoma treatment options in Baxter, MN, this clinical trial (NCT05612100) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Baxter research site is actively enrolling participants for this clinical trial. You'll receive care from experienced breast carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all breast carcinoma clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Baxter, MN

See all breast cancer clinical trials recruiting in Baxter — not just this study.

Browse Breast Cancer Trials in Baxter

Ready to Join in Baxter?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Baxter, MN